3 Types of Executive Team Dysfunction
Transcript
CEOs get a ton of credit or blame for a company's performance. But the entire leadership team is vital to success, and any dysfunction is often overlooked. Sometimes the CEOs leading them don't even see that they're not working. Thomas Keil, management professor at the University of Zurich, and Marianna Zangrillo, a partner at The Next Advisors, have interviewed more than 100 CEOs and senior executives. Their research identifies three main types of failing leadership teams: shark tanks, petting zoos, and mediocracies. And they identify the pitfalls of each pattern and how to turn those teams around. Keil and Zangrillo wrote the HBR article ' Why Leadership Teams Fail.'
Key episode topics include: leadership, teams, strategy execution, decision making and problem solving, managing people, change management
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
C3 AI Restructures Sales and Services Organizations to Accelerate Growth
New leadership includes Chief Commercial Officer, General Manager of EMEA, North America REDWOOD CITY, Calif., August 08, 2025--(BUSINESS WIRE)--C3 AI (NYSE: AI), the Enterprise AI application software company, in the course of Q1, has restructured its global sales and services organization, including new leadership. That restructuring is now complete. New leadership includes: Rob Schilling joins C3 AI as EVP and Chief Commercial Officer, responsible for all Sales, customer-facing teams, and Alliances, effective June 16, 2025. Schilling is a seasoned enterprise application sales leader. His prior experience includes SVP, ERP, Oracle, responsible for a billion-dollar cloud application business; GVP, Nokia Software; CEO, SpaceTime; SVP, SAP Americas; Chief Customer Officer, SAP Japan; and SVP of Sales at Siebel Systems. He brings almost a quarter century of senior enterprise sales leadership to lead the C3 AI go-to-market effort globally. John Kitchingman joins C3 AI as General Manager, EMEA, effective June 30, 2025. He previously served as SVP, Global Customer Engagement at Dassault Systèmes and VP and Global Sales Leader, IBM Global Services. Jeff Cosseboom joins C3 AI as Group Vice President, North America East Sales. He brings over three decades of enterprise sales experience as Chief Revenue Officer, Palladin Technologies; Area VP, Salesforce-Vlocity; VP, SAP; and GVP, Siebel Systems/Oracle. Lars Farnstrom joins C3 AI as Group Vice President, Nordics. He is also an exceptionally experienced technology leader, including as CEO, VP, Nordics, C3 AI; CEO, Raw Lab; VP, Sales Northern Europe, C3 AI; and Group Director, CRM, Siebel Systems. Alex Amato, Group Vice President of Customer Services and an executive with C3 AI for nine years, has been promoted to assume responsibility for all professional services and customer service operations, reporting to Rob Schilling. In the course of Q1, he has restructured the services organization to ensure a consistent and universal focus on rapid and significant value realization for all C3 AI engagements. "The good news is we have completely restructured the sales and services organization, including new and highly experienced leadership across the board to ensure a return to accelerating growth and increased customer success at C3 AI. The bad news is that sales results in Q1 were completely unacceptable. Having given this a lot of thought, I attribute this to two factors. One: It is clear that in the short term, the reorganization with new leadership had a disruptive effect. Two: As we have previously announced, I have had a number of health issues in the past six months including multiple hospitalizations and vision impairment. Unfortunately, dealing with these health issues prevented me from participating in the sales process as actively as I have in the past. With the benefit of hindsight, it is now apparent that my active participation in the sales process may have had a greater impact than I previously thought. That being said, as we enter Q2, we have new leadership in place, a restructuring completed, an extraordinarily large market opportunity, a superlative product offering, and exceptional levels of customer satisfaction, and I am confident the company is positioned to accelerate going forward," said Thomas M. Siebel, Chairman and CEO, C3 AI. "I am pleased to also report that, but for vision impairment, my health has improved dramatically. I am feeling strong and am fully engaged. As you also know, we are actively engaged in an executive search for a successor CEO at C3 AI and are moving expeditiously to identify some excellent candidates in short order." Use of Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "continue," "may," "would," "will" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding our market opportunity, our sales and customer opportunity pipeline, the results of restructuring our sales and services organizations, the success of our new sales leadership structure, customer satisfaction, the outcome of our search for a new Chief Executive Officer, and our business strategies, plans, and objectives for future operations. We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. These forward-looking statements are subject to a number of risks and uncertainties, including our history of losses and ability to achieve and maintain profitability in the future, our historic dependence on a limited number of existing customers that account for a substantial portion of our revenue, our ability to attract new customers and retain existing customers, market awareness and acceptance of enterprise AI solutions in general and our products in particular, the length and unpredictability of our sales cycles and the time and expense required for our sales efforts. Some of these risks are described in greater detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the fiscal year ended April 30, 2025, and other filings and reports we make the Securities and Exchange Commissions from time to time, including our Quarterly Report on Form 10-Q that will be filed for the fiscal quarter ended July 31, 2025, although new and unanticipated risks may arise. Certain of the future events and trends discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, achievements, or events and circumstances reflected in the forward-looking statements will occur. Except to the extent required by law, we do not undertake to update any of these forward-looking statements after the date of this press release to conform these statements to actual results or revised expectations. About Inc. C3 AI is the Enterprise AI application software company. C3 AI delivers a family of fully integrated products including the C3 Agentic AI Platform, an end-to-end platform for developing, deploying, and operating enterprise AI applications, C3 AI applications, a portfolio of industry-specific SaaS enterprise AI applications that enable the digital transformation of organizations globally, and C3 Generative AI, a suite of domain-specific generative AI offerings for the enterprise. View source version on Contacts C3 AI Public Relations EdelmanLisa Kennedy415-914-8336pr@ Investor Relations ir@ Sign in to access your portfolio
Yahoo
27 minutes ago
- Yahoo
Ardagh Group Transaction Support Agreement
Ardagh has obtained the support of over 90% of holders under each of the SSN Indentures and SUN Indentures and over 75% of holders under the PIK Notes Indenture LUXEMBOURG, Aug. 9, 2025 /PRNewswire/ -- Ardagh Group S.A. (the "Company" or "Ardagh") is pleased to announce that, as of August 8, 2025, holders of over 90% of the senior secured notes (the "SSNs", and the indentures pursuant to which the SSNs are issued being the "SSN Indentures") issued by Ardagh Packaging Finance PLC and Ardagh Holdings USA Inc., over 90% of the senior unsecured notes issued by Ardagh Packaging Finance PLC and Ardagh Holdings USA Inc. (the "SUNs", and the indentures pursuant to which the SUNs are issued being the "SUN Indentures") and over 75% of the senior secured toggle notes due 2027 issued by ARD Finance S.A. (the "PIK Notes", and the indenture pursuant to which the PIK Notes are issued being the "PIK Notes Indenture"), have entered into the transaction support agreement dated July 28, 2025, between, among others, the Company and certain holders of SSNs, SUNs and PIK Notes (the "TSA"). The Company encourages all remaining holders of the SSNs, SUNs and PIK Notes to accede to the TSA prior to the early bird deadline of August 12, 2025, in order to receive the Early Consent Consideration (as defined in the TSA), which is summarized in the appendix of this announcement. Holders of SSNs, SUNs and PIK Notes who wish to access further information relating to the Agreed Recapitalization Transaction and accede to the TSA to contact Kroll Issuer Services Limited, the exchange and tabulation agent, via email at ard@ Appendix Summary of Early Consent Consideration Capitalized terms used in this summary appendix shall have the meaning given to the equivalent defined term in the TSA. This appendix is only intended to provide a summary of the Early Consent Consideration construct set out in Part A (Implementation Term Sheet) of Exhibit A to the TSA for ease of reference and the TSA should be consulted for further detail. For the avoidance of doubt, this summary assumes that all relevant conditions under the TSA have been satisfied. The Early Consent Time is currently August 12, 2025. Instrument Consideration Existing SSNs Consenting SSN Holders who sign up or accede to the TSA on or before the Early Consent Time will exchange their Existing SSNs at par into new Exchange SSNs. Each other Consenting SSN Holder or Non-Consenting SSN Holder will exchange their Existing SSNs at a rate of $800 in principal amount of Exchange SSNs for each $1,000 in principal amount of Existing SSNs. Existing SUNs Each Consenting SUN Holder and Non-Consenting SUN Holder will receive their pro rata portion of 70% of the 92.5% allocation of EquityCo Shares. In addition to the allocation in the paragraph above, each Consenting SUN Holder who signs up to or accedes to the TSA on or before the Early Consent Time will additionally receive their pro rata share of 30% of the 92.5% allocation of EquityCo Shares. Existing PIK Notes Each Consenting PIK Holder and Non-Consenting PIK Holder will receive their pro rata portion of 70% of the 7.5% allocation of EquityCo Shares. In addition to the allocation in the paragraph above, each Consenting PIK Holder who signs up to or accedes to the TSA on or before the Early Consent Time will additionally receive their pro rata share of 30% of the 7.5% allocation of EquityCo Shares. Ardagh Group is a global supplier of infinitely recyclable metal and glass packaging for brand owners around the world. Ardagh operates 58 metal and glass production facilities in 16 countries, employing approximately 19,000 people with sales of approximately $9.1 billion in 2024. Disclaimer This release does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor will there be any sale of securities referred to in this announcement, in any jurisdiction, including the United States, in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. Securities may not be offered or sold in the United States absent registration under the U.S. Securities Act of 1933, or an exemption from registration. This release may contain "forward-looking" information. The forward-looking information is based upon certain assumptions about future events or conditions and is intended to illustrate hypothetical results under those conditions. Actual events or conditions are unlikely to be consistent with and may materially differ from those assumed. Any views or opinions expressed in this release (including statements or forecasts) constitute the judgement of the Company as of the date of this material and are subject to change without notice. You are cautioned not to place undue reliance on any forward-looking information. Any projections or forecasts in this release are illustrative only and have been based on the estimates and assumptions when the Company's business plan was prepared. Such estimates and assumptions may or may not prove to be correct. These projections do not constitute a forecast or prediction of actual results and there can be no assurance that the projected results will actually be realized or achieved. Actual results may depend on future events which are not in the Company's control and may be materially affected by unforeseen economic or other circumstances. Contacts: Media:Pat Walsh, Murray ConsultantsTel.: +353 1 498 0300 / +353 87 2269345Email: pwalsh@ Conor McClafferty, FGS GlobalEmail: Investors:Email: investors@ View original content to download multimedia: SOURCE Ardagh Group S.A. Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Why Novo Nordisk Stock Flew Higher on Friday
Key Points An archrival's investigational obesity drug didn't perform spectacularly in a recent clinical study. Its results lagged that of Novo Nordisk's star product, Wegovy. 10 stocks we like better than Novo Nordisk › On Friday, the stock of Novo Nordisk (NYSE: NVO) continued to be affected by results from the lab the previous day. The interesting twist: It wasn't the company conducting the research. Rather, it was the Danish pharmaceutical company's No. 1 rival. Appreciative investors bid up Novo Nordisk's stock in a mini-rally that extended into Friday; the company's share price added nearly 5% during today's session. That looked especially good next to the trajectory of the S&P 500 index, which could only manage a 0.8% increase on the day. News from the lab The previous day, that peer, Eli Lilly, reported the top-line results from a phase 3 trial of orforglipron. This is a pipeline GLP-1 drug akin to Novo Nordisk's Wegovy or Eli Lilly's own Zepbound, targeting weight loss. A key difference is that it's an oral medication, and thus easier to administer than the jabs of Wegovy and Zepbound. The company revealed that the highest dose of the medication led to an average of nearly 12% loss in body weight for the study's participants. The trial was conducted over a stretch of 72 weeks. Many analysts and pharmaceutical industry observers were expecting a higher rate: 15% or so. More than a few believe orforglipron's rate compares unfavorably to Wegovy, hence Novo Nordisk's small share-price pop. This, despite Eli Lilly's positive spin on the trial. In an interview on CNBC's Squawk Box, CEO David Ricks said that he was not disappointed with these results: "It's right on thesis for us." "The goal was to create an oral pill that was convenient and can be made at a huge scale, really, for the mass market, and had weight loss that was competitive with other single-acting GLP-1s, and that's what we've achieved," Ricks said. Weight loss for gain This may be so, but GLP-1 weight loss drugs are a duopoly at the moment, with Wegovy and Zepbound, so the segment is tight and competitive. Any advantage is large, and with this latest news, Novo Nordisk seems to be enjoying one. Should you buy stock in Novo Nordisk right now? Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,563!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,108,033!* Now, it's worth noting Stock Advisor's total average return is 1,047% — a market-crushing outperformance compared to 181% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. Why Novo Nordisk Stock Flew Higher on Friday was originally published by The Motley Fool Sign in to access your portfolio
